NCT05413044Completed
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 140706 (actual)
- First submitted
- 7 Jun 2022
- Start date
- 1 Jul 2019
- Primary completion date
- 22 Aug 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis, Psoriatic arthritis, Rheumatoid arthritis
- NCT number
- NCT05413044
What you commit to
- Study type: Observational
- Participants enrolled: 140706
- From 1 Jul 2019 to the primary completion date, 22 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Not applicable
Who the study is looking for
- Diagnosis of RA or PsA
- ≥18 years at index treatment initiation
- Participants starting treatment with:
- abatacept
- non-targeted DMARDs
- targeted DMARD
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Princeton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.